Copaxone sales don’t slip amid generic competition


Teva’s Copaxone drug was widely expected to see a significant drop in sales after Sandoz and Momenta launched their generic version of the drug. Despite the multiple sclerosis drug seeing generic competition, Teva’s branded product has still seen impressive sales. According to IMS data, the molecule share for 3TW has moved up to 70.7% TRx share at the end of the first week of August. The generic version’s molecule share has stayed around 5% for around four straight weeks.

Read the source article at Pharmacy Choice

About the Author

Related Posts

Leave a Reply